May 19, 2021

Colchicine in Patients Admitted to Hospital with COVID-19 (RECOVERY) a Randomised Controlled Open-Label Platform Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• [Pre-print, not peer-reviewed] The anti-inflammatory drug colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progression to invasive mechanical ventilation (IVM) or death among adults hospitalized with COVID-19 in an analysis of the RECOVERY trial (a randomized, placebo-controlled open-label trial). In both the treatment (n=5610) and control (n=5730) groups, 28-day mortality was 28%, median duration of hospital stay was 10 days, and 25% of patients progressed to IVM or death among those not on IVM at baseline. Results were consistent across pre-specified patient subgroups of pat.

Horby et al. (May 18, 2021). Colchicine in Patients Admitted to Hospital with COVID-19 (RECOVERY) a Randomised Controlled Open-Label Platform Trial. Pre-print downloaded May 19 from https://doi.org/10.1101/2021.05.18.21257267